ProKidney logo

ProKidney(NASDAQ) PROK

Market Cap$300.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-86%
5 Year-85%
1 Year-56%
1 Month-19%
Premium Feature
Moneyball Superscore
44/100
$1.46
+1.04%
+0.02Today
After hours$1.44-$0.02 (-1.03%)
ProKidney last closing stock price
MetricPriceDate
Last closeUSD 1.442026-10-21
ProKidney stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.04%USD 1.472026-10-14
1 month-18.87%USD 1.782026-09-21
3 month-5.26%USD 1.522026-07-23
Year to date-35.71%USD 2.242025-12-31
1 year-56.36%USD 3.302025-10-21
3 year-18.64%USD 1.772023-10-20
5 year-85.41%USD 9.872021-10-22
Since inception-85.76%USD 10.112021-06-30

ProKidney Financials at a Glance

Market Cap

$300.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$818.00K

Net Income (TTM)

-$86.71M

EPS (TTM)

-$0.55

P/E Ratio

-2.61

Dividend

$0.00

Beta (Volatility)

1.42 (Average)

Price

$1.46

Volume

601,289.896

Open

$1.44

Previous Close

$1.44

Daily Range

$1.44 - $1.49

52-Week Range

$1.30 - $3.48

Estimated Earnings Date

Nov 9, 2026

PROK News

Foolcom-Featured.png

ProKidney Reports 78 Percent Gain in Q2

Motley Fool Markets TeamAug 12, 2025
happy-investors-checking-holdings

Meet the Biotech Stock That Rocketed 775% Higher

Cory RenauerJul 22, 2025
Person working in a lab.

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?

David Jagielski, CPAJul 17, 2025
adaptimmune

Why Shares of ProKidney Were Dropping Thursday

James HalleyOct 12, 2023

PROK: Motley Fool Moneyball Superscore

44

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProKidney

ProKidney NASDAQ:PROK makes treatments to help people keep their kidneys working. It uses a person's own cells to repair their damaged organs. This helps patients who have kidney disease caused by diabetes.

A New Way to Treat Kidneys

  • rilparencel: Lead cell therapy candidate currently in Phase 3 clinical trials; designed to preserve kidney function in patients with advanced chronic kidney disease and type 2 diabetes.
  • Selected Renal Cells: Autologous cells taken from a patient and prepared for reinjection; eliminates the need for the lifelong immune-suppressing drugs required for traditional transplants.
  • Leasing Services: Property management for two buildings in North Carolina; accounts for 100% of revenue as the company has no approved products.

Building a Foundation for Growth

  • Completed a domestication process to move the legal home from the Cayman Islands to Delaware on July 1, 2025.
  • Entered a sales agreement with Jefferies LLC in July 2025 to sell up to $200 million in stock over time.
  • Amended the Phase 3 study protocol for rilparencel to focus on specific stages of chronic kidney disease.
  • Expanded internal manufacturing capacity through a $3.4 million investment during the six-month period ended June 30, 2026.

The Personalized Medicine Advantage

The company uses a proprietary process to create personalized medicine from a patient's own tissue. This approach targets the underlying cause of kidney decline rather than just managing symptoms or preparing for failure.

Key Figures and Funding

  • Net loss was $46.4 million for the three months ended June 30, 2026.
  • Research and development expenses rose to $69.9 million for the six-month period ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities are expected to fund operations into mid-2027.
  • Market capitalization was $568.3 million according to recent data.

The Path Ahead

ProKidney has transitioned from an early-stage researcher to a late-clinical-stage developer of personalized cell therapies. Its shift toward late-stage trials and expanded manufacturing reflects a focus on bringing laboratory science to patients with chronic disease.

AI Generated • Aug 11, 2026

Industry

Biotechnology

Sector

Health Care

Employees

231

CEO

Bruce Culleton, MD, MBA

Website

www.prokidney.com

Headquarters

Winston-Salem, NC 27103, US

PROK Financials

Key Financial Metrics (TTM)

Gross Margin

-252.57%

Operating Margin

-21664.55%

Net Income Margin

-10599.76%

Return on Equity

8.83%

Return on Capital

N/A

Return on Assets

-34.82%

Earnings Yield

-38.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$300.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

208.93M

Volume

601.29K

Avg. Volume

1.31M

Financials (TTM)

Gross Profit

-$2.07M

Operating Income

-$177.22M

EBITDA

-$159.91M

Operating Cash Flow

-$141.17M

Capital Expenditure

-$18.57M

Free Cash Flow

-$159.73M

Cash & ST Invst.

$181.56M

Total Debt

$3.52M

ProKidney Performance Analysis

ProKidney annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 76,000N/A
20252025-12-31USD 893,0001075.0%
ProKidney sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1.8%
Q42025-12-313.7%
Q12026-03-310.4%
Q22026-06-30-33.6%
ProKidney annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.7695.9%
20232023-12-31USD -0.57-67.3%
20242024-12-31USD -0.628.7%
20252025-12-31USD -0.52-17.6%
ProKidney sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.7%
Q42025-12-31-16.7%
Q12026-03-31-14.3%
Q22026-06-306.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$150.00K

-32.1%

Gross Profit

$150.00K

-32.1%

Gross Margin

100.00%

N/A

Market Cap

$300.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.30M

N/A

Employees

231

N/A

Net Income

-$28.42M

-71.7%

EBITDA

-$44.76M

-29.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$181.56M

-38.4%

Total Debt

$3.52M

-20.3%

Accounts Receivable

$956.00K

-46.1%

Inventory

$0.00

N/A

Long Term Debt

$2.39M

-31.9%

Short Term Debt

$1.13M

+25.0%

Return on Assets

-34.82%

N/A

Return on Invested Capital

-78.31%

N/A

Free Cash Flow

-$44.21M

-28.0%

Operating Cash Flow

-$40.37M

-28.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MENSJyong Biotech Ltd. Ordinary Shares
$1.89+1.61%
DMACDiaMedica Therapeutics Inc.
$8.69+0.23%
UNCYUnicycive Therapeutics, Inc.
$3.87+1.84%
ARDXArdelyx, Inc.
$3.13-2.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$159.31+7.80%
NFLXNetflix
$65.04-5.31%
NVDANvidia
$221.97+2.54%
TAT&T
$21.91-6.45%

Questions About PROK

What is the current price of ProKidney?

ProKidney is trading at $1.44 per share.

What is the 52-week range for ProKidney?

Over the past 52 weeks, ProKidney has traded between $1.30 and $3.48.

How much debt does ProKidney have?

As of the most recent reporting period, ProKidney reported total debt of $3.52M.

How much cash does ProKidney have on hand?

ProKidney reported $74.87M in cash and cash equivalents in its most recent financial results.

What is ProKidney’s dividend yield?

ProKidney does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services